Cite Filings / ENTA / 0000950170-25-021421
Feed Companies Filings Check
Sign in
Cite Filings

Pages

  • Feed
  • Companies
  • Filings
  • Check a claim

Account

  • Sign in
  • Create an account
Support (opens in new tab)
SCHEDULE 13D/A

Beneficial Ownership Report

ENANTA PHARMACEUTICALS INC · Filed 2025-02-14 · Acc 0000950170-25-021421

Documents 1

  • SCHEDULE 13D/A Beneficial Ownership Report , xslSCHEDULE_13D_X01/primary_doc.xml

Around this filing

  • 2025-02-14 4 Chief Business Officer gave up 3,326 shares (to pay taxes)
  • 2025-02-14 4 Chief Product Strategy Officer gave up 3,326 shares (to pay taxes)
  • 2025-02-14 4 Chief Medical Officer gave up 2,861 shares (to pay taxes)
  • 2025-02-14 4 Chief Scientific Officer gave up 4,324 shares (to pay taxes)
  • 2025-02-14 4 Chief Fin. & Admin Officer gave up 3,326 shares (to pay taxes)
  • 2025-02-14 4 President and CEO gave up 7,484 shares (to pay taxes)
  • 2025-02-14 SCHEDULE 13D/A Beneficial Ownership Report

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)

Stakes reported in this filing

Stake history · largest stake in each 13D and 13G

  1. 2026-11-16 SCHEDULE 13G · ADAR1 Capital Management, LLC 6.0%
  2. 2026-11-16 SCHEDULE 13G/A · Farallon Capital Management, L.L.C. 3.3%
Loading xslSCHEDULE_13D_X01/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…